Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc (NQ: ONCY )

1.040 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 1.040 (3)
Ask (Size) 1.050 (10)
Prev. Close 1.040
Today's Range 1.040 - 1.040
52wk Range 0.8830 - 3.394
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biotech Innovations Paving the Way in Breast Cancer Fight
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death Product Safety
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer Overall survival results from the randomized HR+/HER2- metastatic... 
Via FinancialNewsMedia
Exposures Product Safety

Performance

YTD
-21.21%
-21.21%
1 Month
+0.97%
+0.97%
3 Month
-16.13%
-16.13%
6 Month
-38.46%
-38.46%
1 Year
-7.96%
-7.96%

More News

Read More
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
Via FinancialNewsMedia
Recap: Oncolytics Biotech Q4 Earnings
Via Benzinga
A Preview Of Oncolytics Biotech's Earnings
Via Benzinga
ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q4 2023
Via InvestorPlace
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
Via FinancialNewsMedia
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
Via Newsfile
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
Via FinancialNewsMedia
Earnings Scheduled For March 7, 2024
Via Benzinga
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
Via FinancialNewsMedia
Cancer Immunotherapy Stocks – Tapping into Immune Systems for Next Generation Treatments
Via FinancialNewsMedia
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
From FN Media Group LLC
Via GlobeNewswire
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments
Via Newsfile
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
Via FinancialNewsMedia
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
Via FinancialNewsMedia
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
From FN Media Group LLC
Via GlobeNewswire
Pancreatic Cancer Treatments Poised for Major Advances in 2024
Via FinancialNewsMedia
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
Via FinancialNewsMedia
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
Via FinancialNewsMedia
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
From FN Media Group LLC
Via GlobeNewswire
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
Via FinancialNewsMedia
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
Via FinancialNewsMedia
Topics Death
Exposures Death
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance
Via FinancialNewsMedia
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.